IMHO, Ramaswamy is a fast-talking, articulate con man. My gut says he a decepticon. What does the Wayback machine have to say? It can be found here and the ealiest it goes back is Jan. 29, 2021. From Wikipedia 01-29-21:

Vivek Ramaswamy (born August 9, 1985) is an American entrepreneur in the biotechnology sector. He is the founder and executive chairman of the biopharmaceutical company Roivant Sciences. Prior to founding Roivant in 2014, Ramaswamy co-founded a technology company and was a partner at an investment firm. He is a graduate of Harvard College and Yale Law School and has written about the undue influence of corporate power on American democracy.

As of April 2017, he is worth an estimated $600 million.[1]

Personal life and education He is the eldest son in his family. His father worked at General Electric and his mother, Geetha Ramaswamy, is a geriatric psychiatrist.[2]

Ramaswamy graduated from St. Xavier High School in Cincinnati in 2003.[3] He graduated summa cum laude from Harvard College with an A.B. in biology. He then received a J.D. from Yale Law School, where his studies were supported by The Paul & Daisy Soros Fellowships for New Americans. [4]

Ramaswamy is married to Apoorva Tewari Ramaswamy, an otolaryngologist. In 2020, after four weeks of maternity leave, she returned to work as a frontline healthcare worker during the COVID-19 pandemic and was infected while treating patients.[5] Apoorva has recovered from the coronavirus.[6]

Career In 2007, he co-founded and served as President of Campus Venture Network, a technology company that was acquired in 2009 by the Ewing Marion Kauffman Foundation. Ramaswamy worked at QVT Financial from 2007 to 2014, where he was a partner and co-managed the firm’s biotech portfolio.[7] Ramaswamy appeared on the cover of Forbes magazine in 2015.[8]

Ramaswamy is the founder of the pharmaceutical company Roivant Sciences. Ramaswamy served as CEO of the company until 2021 when he became executive chairman. Roivant is focused on applying technology to drug development and has built numerous subsidiary biotech and healthcare technology companies, several of which are publicly listed. The initial public offering for Roivant subsidiary Axovant in 2015 raised $360 million.[9]

Ramaswamy served on the Board of Directors of Myovant Sciences, a subsidiary of Roivant Sciences focused on the treatment of women’s health diseases and other endocrine-related disorders. Myovant, formed in April 2016, raised $218 million in its initial public offering, the largest biotech IPO of 2016.[10]

Ramaswamy serves on the Board of Directors of Sumitovant Biopharma. Sumitovant is the result of a $3 billion transaction in 2019 which transferred ownership stakes in five companies in the Roivant family, and includes investigational medicines which generated four successful Phase 3 studies in 2019.[11]

In 2020, Ramaswamy served on the Ohio COVID-19 Response Team.[12]

In January 2021, Ramaswamy stepped down as CEO of Roivant Sciences and became executive chairman of the company's board.[13]

Publications

• The Chimera Question, New York Times, July 16, 2007[14]
• This Pharma Company Stays Innovative by Doing Two Things, Harvard Business Review, March 14, 2017[15]
• The ‘Stakeholders’ vs. the People, Wall Street Journal, February 12, 2020[16]
• COVID-19 and American Identity, The Dispatch, July 14, 2020[17]
• Antitrust Can't Bust a Monopoly of Ideas, Wall Street Journal, August 5, 2020[18]
• End Corporate Privilege by Limiting Limited Liability, Newsweek, October 9, 2020[19]
• The Pluralism Within, National Review, October 29, 2020[20]
• Save the Constitution from Big Tech, Wall Street Journal, January 11, 2021[21]